Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2][3].
Molecular Weight:
(146.08 kDa)
Purity:
99.4
CAS Number:
[1610761-46-0]
Target:
CCR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
